Argos Therapeutics, Inc. (NASDAQ:ARGS) was the recipient of a large decrease in short interest in the month of October. As of October 13th, there was short interest totalling 2,706,234 shares, a decrease of 21.1% from the September 29th total of 3,429,642 shares. Based on an average daily trading volume, of 5,538,609 shares, the days-to-cover ratio is presently 0.5 days. Approximately 8.9% of the company’s stock are sold short.
Argos Therapeutics (NASDAQ:ARGS) last announced its earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.21) EPS for the quarter, topping the consensus estimate of ($0.22) by $0.01. The firm had revenue of $0.07 million for the quarter, compared to the consensus estimate of $0.10 million. Argos Therapeutics had a negative net margin of 12,391.15% and a negative return on equity of 1,532.49%.
Separately, Zacks Investment Research lowered shares of Argos Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, August 14th. One equities research analyst has rated the stock with a sell rating and three have assigned a hold rating to the company’s stock. Argos Therapeutics presently has a consensus rating of “Hold” and a consensus price target of $4.13.
WARNING: This article was published by Community Financial News and is the property of of Community Financial News. If you are accessing this article on another domain, it was illegally stolen and republished in violation of United States & international copyright legislation. The original version of this article can be read at https://www.com-unik.info/2017/11/03/argos-therapeutics-inc-args-sees-significant-drop-in-short-interest.html.
Argos Therapeutics Company Profile
Argos Therapeutics, Inc (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies.
What are top analysts saying about Argos Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Argos Therapeutics Inc. and related companies.